Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV Vaccine LYB005 in Healthy Adults
NCT06442241Phase 1Active, not recruiting
- Sponsor
- Patronus Biotech
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of LYB005 in respiratory syncytial virus infection (RSV), sponsored by Patronus Biotech. Primary endpoints: Immediate Adverse Events, Solicited Local and Systemic Adverse Events and Unsolicited Adverse Events at 7 days and 3 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
LYB005
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06442241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442241.